Drug Profile
Selonabant - Anebulo Pharmaceuticals
Alternative Names: ANEB 001; V-24343Latest Information Update: 17 Nov 2023
Price :
$50
*
At a glance
- Originator Vernalis
- Developer Anebulo Pharmaceuticals; Vernalis
- Class Drug withdrawal therapies; Obesity therapies; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Substance-related disorders
- Discontinued Obesity
Most Recent Events
- 14 Nov 2023 Anebulo Pharmaceuticals plans two phase III registrational trials for Substance-related disorders in the first half of 2024
- 26 Aug 2023 Anebulo Pharmaceuticals completes a phase II trial in Substance-related disorders (In volunteers) in Netherlands (ISRCTN45282100) (NCT05282797)
- 21 Aug 2023 Adverse events data and pharmacokinetics data from phase II trial was released by Anebulo Pharmaceuticals